再生医学
诱导多能干细胞
医学
药物发现
疾病
个性化医疗
精密医学
康复
药品
食品药品监督管理局
重症监护医学
干细胞
生物信息学
胚胎干细胞
药理学
病理
物理疗法
生物
基因
生物化学
遗传学
作者
David L. Mack,Xuan Guan,Ashley L. Wagoner,Stephen J. Walker,Martin K. Childers
出处
期刊:American Journal of Physical Medicine & Rehabilitation
[Ovid Technologies (Wolters Kluwer)]
日期:2014-11-01
卷期号:93 (11): S155-S168
被引量:18
标识
DOI:10.1097/phm.0000000000000141
摘要
Advances in regenerative medicine technologies will lead to dramatic changes in how patients in rehabilitation medicine clinics are treated in the upcoming decades. The multidisciplinary field of regenerative medicine is developing new tools for disease modeling and drug discovery based on induced pluripotent stem cells. This approach capitalizes on the idea of personalized medicine by using the patient’s own cells to discover new drugs, increasing the likelihood of a favorable outcome. The search for compounds that can correct disease defects in the culture dish is a conceptual departure from how drug screens were done in the past. This system proposes a closed loop from sample collection from the diseased patient, to in vitro disease model, to drug discovery and Food and Drug Administration approval, to delivering that drug back to the same patient. Here, recent progress in patient-specific induced pluripotent stem cell derivation, directed differentiation toward diseased cell types, and how those cells can be used for high-throughput drug screens are reviewed. Given that restoration of normal function is a driving force in rehabilitation medicine, the authors believe that this drug discovery platform focusing on phenotypic rescue will become a key contributor to therapeutic compounds in regenerative rehabilitation.
科研通智能强力驱动
Strongly Powered by AbleSci AI